
Quarterly report 2025-Q2
added 07-30-2025
Guardant Health EPS Ratio 2011-2025 | GH
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Guardant Health
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -3.56 | -4.28 | -6.41 | -4 | -2.6 | -0.84 | -2.8 | -7.07 | -3.53 | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.84 | -7.07 | -3.9 |
Quarterly EPS Ratio Guardant Health
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.8 | -0.77 | - | -0.88 | -0.84 | -0.94 | - | -0.73 | -0.67 | -1.3 | - | -1.58 | -2.25 | -1.21 | - | -1.06 | -0.96 | -1.09 | - | -0.78 | -0.57 | -0.29 | - | -0.14 | -0.13 | -0.3 | - | -1.94 | -1.75 | -1.16 | - | -2.76 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -0.13 | -2.76 | -1.04 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Brainsway Ltd.
BWAY
|
-0.24 | $ 19.29 | -1.73 % | $ 99.4 M | ||
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 40.09 | -0.27 % | $ 1.11 B | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 21.26 | -2.34 % | $ 229 M | ||
|
DarioHealth Corp.
DRIO
|
1.93 | $ 10.04 | -0.99 % | $ 285 M | ||
|
DexCom
DXCM
|
1.4 | $ 67.42 | 0.84 % | $ 26 B | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-4.67 | $ 101.54 | -0.05 % | $ 18.8 B | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
BioNano Genomics
BNGO
|
-88.1 | $ 1.52 | -0.65 % | $ 1.93 M | ||
|
Danaher Corporation
DHR
|
5.33 | $ 231.47 | 0.28 % | $ 169 B | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 27.01 | -0.55 % | $ 817 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
Myriad Genetics
MYGN
|
-1.41 | $ 6.55 | -0.15 % | $ 593 M | ||
|
Neogen Corporation
NEOG
|
-5.03 | $ 7.14 | -0.14 % | $ 1.55 B | ||
|
CareDx, Inc
CDNA
|
-3.54 | $ 19.73 | -1.45 % | $ 1.06 B | ||
|
Celcuity
CELC
|
-2.83 | $ 102.61 | 0.25 % | $ 4.05 B | ||
|
National Research Corporation
NRC
|
1.26 | $ 18.81 | -1.05 % | $ 462 M | ||
|
Anixa Biosciences
ANIX
|
-0.39 | $ 3.42 | 3.64 % | $ 109 K | ||
|
OPKO Health
OPK
|
0.02 | $ 1.3 | -0.76 % | $ 902 M | ||
|
Co-Diagnostics
CODX
|
-1.2 | $ 0.24 | -1.79 % | $ 7.04 M | ||
|
Pacific Biosciences of California
PACB
|
-1.21 | $ 1.88 | 3.3 % | $ 477 M | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
IQVIA Holdings
IQV
|
7.57 | $ 226.02 | 0.39 % | $ 41 B | ||
|
Koninklijke Philips N.V.
PHG
|
3.67 | $ 26.98 | 0.37 % | $ 20 B | ||
|
Precipio
PRPO
|
-4.51 | $ 23.89 | 2.56 % | $ 31 M | ||
|
QIAGEN N.V.
QGEN
|
0.38 | $ 45.48 | -0.29 % | $ 10.1 B | ||
|
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M | ||
|
Sotera Health Company
SHC
|
0.16 | $ 17.7 | 1.67 % | $ 5.01 B | ||
|
Illumina
ILMN
|
-7.69 | $ 135.32 | -0.64 % | $ 21.5 B | ||
|
Charles River Laboratories International
CRL
|
0.2 | $ 203.16 | 0.14 % | $ 10.4 B | ||
|
ENDRA Life Sciences
NDRA
|
-5.55 | $ 5.1 | - | $ 2.74 M | ||
|
Twist Bioscience Corporation
TWST
|
-1.3 | $ 33.58 | -0.77 % | $ 2.01 B | ||
|
Quest Diagnostics Incorporated
DGX
|
7.78 | $ 175.92 | 0.48 % | $ 19.5 B | ||
|
Biodesix
BDSX
|
-0.33 | $ 6.82 | 1.04 % | $ 884 M | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
Laboratory Corporation of America Holdings
LH
|
8.89 | $ 254.46 | 0.52 % | $ 21.3 B |